ethyl 2-(diethoxyphosphoryl)-4-methylpentanoate | 123803-19-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: ethyl 2-(diethoxyphosphoryl)-4-methylpentanoate
• 英文别名: ethyl 2-diethylphosphono-4-methylpentanoate；ethyl 2-(diethoxyphosphinyl)-4-methylpentanoate；ethyl 2-diethoxyphosphoryl-4-methylpentanoate
• CAS: 123803-19-0
• 化学式: C₁₂H₂₅O₅P
• 分子量: 280.301
• InChiKey: WXILOHNZGUVHBH-UHFFFAOYSA-N

物化性质

• 沸点：
  342.3±25.0 °C(Predicted)
• 密度：
  1.046±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(diethoxyphosphoryl)-4-methylpentanoate 在 palladium on activated charcoal 氢气 、 sodium hydride 、 三氟乙酸 作用下， 以 吡啶 、 乙二醇二甲醚 、 乙醇 为溶剂， 反应 8.5h， 生成 (3S,6R)-3,6-bis(2-methylpropyl)piperidin-2-one
  参考文献：
  名称：

  Syntheses and biological activities of bombesin analogs modified in the C-terminal dipeptide part

  摘要：

  Bombesin receptor antagonists are possible therapeutic agents due to their ability to act as inhibitors of cellular proliferation. On the basis of our hypothesis on the mechanism of action of gastrin associating an activating enzyme system to the receptor and on the results reported in the litterature, we have synthesized bombesin analogues which have been modified in the C-terminal Leu(13)-Leu(14) amide part. We have shown that modification in the C-terminal part of the bombesin strongly affected the biological activity in rat pancreatic acini. The most potent compound which is described here, H-D-Phe- Gln-Trp-Ala-Val-Gly-His-Leu-psi(CH2)Leu-NH2, was able to recognize the bombesin receptor on rat pancreatic acini (Ki 4.3 nM) and antagonized the bombesin stimulated amylase secretion (Ki 7.7 nM).

  DOI：

  10.1016/s0223-5234(99)80063-4
• 作为产物：
  描述：

  2-溴-4-甲基戊酸 在 硫酸 作用下， 反应 50.0h， 生成 ethyl 2-(diethoxyphosphoryl)-4-methylpentanoate
  参考文献：
  名称：

  [EN] INHIBITORS OF PSEUDOMONAS AERUGINOSA VIRULENCE FACTOR LasB
  [FR] INHIBITEURS DU FACTEUR DE VIRULENCE DE LASB DE PSEUDOMONAS AERUGINOSA

  摘要：

  本发明涉及式（la）的化合物及其作为P. aeruginosa毒力因子LasB的抑制剂的用途。这些化合物在治疗细菌感染，特别是由P. aeruginosa引起的感染中是有用的。

  公开号：

  WO2022043322A1

文献信息

• Renin Inhibitors. I. Synthesis and Structure-Activity Relationships of Transition-State Inhibitors Containing Homostatine Analogues at the Scissile Bond.
  作者：Shugo ATSUUMI、Masato NAKANO、Yutaka KOIKE、Seiichi TANAKA、Kenji MATSUYAMA、Makiko NAKANO、Hajime MORISHIMA

  DOI：10.1248/cpb.40.364

  日期：——

  The synthesis and structure-activity relationships of transition-state renin inhibitors containing the homostatine analogues at the scissile bond are described. These inhibitors incorporate the amino acid side chains corresponding to positions 7-12 (P4-P2') of angiotensinogen. Ethyl, 2-hydroxyethyl and 3-hydroxypropyl groups at position 2 of the homostatine analogues (P1') are more effective for increasing potency than the isopropyl group. A combination of residues at P1, P3 and P4 is important for potency and this result auggests that S1, S3 and S4 form a huge hydrophobic core together in renin.

  描述了含有在切割键处的同胺酸类似物的过渡态肾素抑制剂的合成及其结构-活性关系。这些抑制剂包含了与血管紧张素原第7-12位（P4-P2'）相对应的氨基酸侧链。在同胺酸类似物的第2位（P1'）上的乙基、2-羟乙基和3-羟丙基比异丙基更有效地增加了效力。P1、P3和P4位点的氨基酸残基组合对效力很重要，结果表明S1、S3和S4在肾素中共同形成了一个巨大的疏水核心。
• Asymmetric Dehydrative Cyclization of ω-Hydroxy Allyl Alcohols Catalyzed by Ruthenium Complexes
  作者：Shinji Tanaka、Tomoaki Seki、Masato Kitamura

  DOI：10.1002/anie.200904671

  日期：2009.11.9

  New axially chiral ligands and their allyl esters have been designed and synthesized. The combination of these ligands with [CpRu(CH3CN)3]PF6 has realized highly efficient intramolecular dehydrative cylization of ω‐hydroxy allyl alcohols, to give α‐alkenyl‐substituted cyclic ethers with up to greater than 99:1 enantiomeric ratio without activation of the allylic moieties (see scheme; Cp=cyclopentadienyl

  已经设计并合成了新的轴向手性配体及其烯丙基酯。这些配体与[CpRu（CH 3 CN）3 ] PF 6的结合实现了ω-羟基烯丙醇的高效分子内脱水环化反应，得到对映体比高达99：1的α-烯基取代的环状醚没有活化烯丙基部分（参见方案； Cp ＝环戊二烯基，naph ＝萘基，py ＝吡啶）。
• (&agr;-aminophosphino) peptide derivatives, method for making same and therapeutic applications thereof
  申请人：Institut National de la Sante et de la Recherche Medicale (Inserm)

  公开号：US06518260B1

  公开（公告）日：2003-02-11

  The invention concerns compounds derived from (&agr;-aminophosphino) peptides, of general formula (I), in which R1 and R2 each represents a hydrogen atom or taken together form an imine with the adjacent nitrogen atom; R3 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all these groups capable of being substituted or not, a hydrogen atom, a cycloalkyl group, a cycloalkylmethyl group or finally, a methyl group substituted by a heterocyclic, aromatic or saturated group; R4 represents a phenyl group, a benzyl group, these groups capable of being substituted or not, a hydrogen atom, an alkyl group, analkenyl group or a cycloalkyl group; R5 represents an alkyl group, an alkenyl group, a phenyl group, a benzyl group, all these groups capable of being substituted or not, a hydrogen atom, a cycloalkyl, cycloalkylmethyl group or finally a methyl group substituted by a heterocyclic, aromatic or saturated group; R6, R7 and R8 can in particular represent a hydrogen atom, an alkyl group, a phenyl group substituted or not . . . n is equal to 0 or 1, in the form of enantiomers, diastereoisomers or racemic mixtures, their salts, their method of preparation and their therapeutic applications.

  该发明涉及从(&agr;-氨基膦)肽衍生的化合物，其一般式为(I)，其中R1和R2分别表示氢原子或与相邻氮原子形成亚胺；R3表示烷基、烯基、苯基、苄基，所有这些基团均可被取代或不取代，氢原子、环烷基、环烷基甲基基团或最后，被杂环、芳香或饱和基团取代的甲基基团；R4表示苯基、苄基，这些基团可被取代或不取代，氢原子、烷基、烯基或环烷基；R5表示烷基、烯基、苯基、苄基，所有这些基团均可被取代或不取代，氢原子、环烷基、环烷基甲基基团或最后，被杂环、芳香或饱和基团取代的甲基基团；R6、R7和R8可以特别表示氢原子、烷基、苯基取代或不取代... n等于0或1，以对映异构体、非对映异构体或混合物的形式存在，它们的盐、制备方法和治疗应用。
• N-acylamino acid derivatives and their pharmaceutical compositions
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US05122523A1

  公开（公告）日：1992-06-16

  An N-acylamino acid derivative of the formula: ##STR1## wherein the substituents are herein defined or a salt thereof, which is useful as hypotensive drugs.

  一种公式为：##STR1## 的N-酰氨基酸衍生物，其中取代基如此定义或其盐，可用作降压药物。
• Synthesis of a Homostatine-Containing Renin Inhibitor Which Incorporates a Sulfonemethylene Isostere at Its<i>N</i>-Terminus
  作者：Masato Nakano、Shugo Atsuumi、Yutaka Koike、Seiichi Tanaka、Hiroshi Funabashi、Junko Hashimoto、Mitsuru Ohkubo、Hajime Morishima

  DOI：10.1246/bcsj.63.2224

  日期：1990.8

  is a key reaction for the synthesis of a homostatine analogue. Stereoselective and stereospecific syntheses of a N-terminal precursor, N-[(2R)-3-hydroxy-2-(1-naphthylmethyl)propionyl]-L-norleucine t-butyl ester and a total synthesis of a highly active renin inhibitor, (2RS,4S,5S)-N-isobutyl-5-[[N-[(2S)-2-(1-naphthylmethyl)-3-(2-pyrimidinylsulfonyl)propionyl]-L-norleucyl]amino]-2-ethyl-4-hydroxy-7-methyloctanamide

  以天然他汀为原料合成了一种高抑素类似物 (2RS,4S,5S)N-isobutyl-5-amino-2-ethyl-4-hydroxy-7-methyloctanamide。(4S,5R)-3-benzyloxycarbonyl-5-formyl-4-isobutyl-2,2-二甲基恶唑烷的改良 Horner-Wadsworth-Emmons 反应是合成高抑素类似物的关键反应。N-末端前体的立体选择性和立体特异性合成，N-[(2R)-3-羟基-2-(1-萘基甲基)丙酰基]-L-正亮氨酸叔丁酯和高活性肾素抑制剂的全合成， (2RS,4S,5S)-N-isobutyl-5-[[N-[(2S)-2-(1-naphthylmethyl)-3-(2-pyrimidinylsulfonyl)propionyl]-L-norleucyl]amino]-2-描述了乙基-4-羟基-7-甲基辛酰胺。